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Rhabdomyosarcoma (RMS) is a malignant tumor of soft tissues, more common in childhood, 
mainly located in the head and neck. It presents varied clinical and biological behavior and requires 
individualized management. 
Aim: To describe information on patients with head and neck RMS diagnosed and treated in a 
hospital, and to compare them to results in the literature. Study design: Descriptive and retrospective. 
Materials and Methods: A retrospective analysis of data from 24 patients with head and neck 
rhabdomyosarcoma diagnosed and treated in a hospital from 1994 to 2008. 
Results: The mean age was 7.79 years. According to gender, 54.17 % were males and 45.83 % were 
female. All patients underwent chemotherapy (CT), 62.5% of them also underwent radiotherapy (RT) 
and 16.67% were submitted to surgery. Of the 24 patients, 8 (33.3%) died, 6 (25%) were found free 
of neoplasia and 2 (8.3%) experienced tumor recurrence. 
Conclusion: The RMS of the head and neck often presents with nonspecific symptoms. Individualized 
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INTRODUCTION
Sarcomas are rare mesenchymal malignant neo-
plasms comprising less than 1% of diagnosed cancers in 
the US and about 1% of head and neck cancers in adults.1 
Over 50% of head and neck malignant tumors in children 
are soft tissue sarcomas and lymphomas.
Salivary gland carcinomas, nasopharyngeal carcino-
mas, neuroblastomas, and thyroid carcinomas are other 
less common head and neck tumors in children.2
The rhabdomyosarcoma, a skeletal muscle subtype, 
is the most common soft tissue sarcoma in children,3 
comprising about 50% of these tumors.4 In contrast, adult 
rhabdomyosarcomas comprise less than 10% of all soft 
tissue sarcomas. Its incidence is 3.5% in children aged 
0 to 14 years, and 2% in teenagers aged 15 to 19 years.5
The head and neck are the most common primary 
sites for rhabdomyosarcomas in children and teenagers, 
followed by the genitourinary tract, limbs, thorax, and 
retroperitoneum.3,5
The tumor head and neck subsites include the orbit, 
parameningeal sites (nasopharynx, nasal cavity, paranasal 
sinuses, temporal bone, pterygopalatine fossa, and the 
infratemporal fossa), and non-parameningeal sites.6,7 Tu-
mors that invade the orbit only have a better prognosis.8
Subtypes may be histologically classified as: 
embryonic (which may be subdivided into embryonic, 
botryoid, and spindle cell tumors), alveolar, or pleomor-
phic.3,5,7,8 In children, about 60% are embryonic tumors, 
20% are alveolar tumors, 15% are not classified, and 5% are 
pleomorphic tumors.5 The embryonic subtype has a better 
prognosis in children, but is more aggressive in adults. 
The alveolar subtype has a poor outcome because of its 
propensity to metastasize at a distance. The pleomorphic 
subtype occurs predominantly in adults.4,9,10 The majority 
of rhabdomyosarcoma cases occurs randomly, with no 
risk factors, although a small proportion of these tumors 
are associated with genetic conditions.5
The diagnosis should include a complete medical 
history, a physical examination, a complete blood count, 
the blood chemistry profile including liver enzymes, nasal 
endoscopy, computed tomography (CT), magnetic reso-
nance imaging (MRI) and a biopsy for pathology.3 Signs 
and symptoms depend on tumor location. Sometimes the 
tumor may not be detected in the physical examination, 
but may become apparent because of pain or functional 
disorders.11 The tumor often presents as a painless neck 
mass.2 Nasal block, rhinorrhea and recurring otitis media 
are the most common presenting symptoms.9 Rapidly 
progressive eye proptosis is a common manifestation in 
tumors of the orbit.11 There are no pathognomonic endos-
copic findings in rhabdomyosarcomas. Some tumors in 
the nasal cavity - or altered mucosa - and small tumors in 
the paranasal sinuses where the sinus walls remain intact 
may not be detected endoscopically.9,12
CT shows the extent of disease and its relation 
with vital structures. Bone remodeling suggests benign 
or slow-growing tumors, while bone destruction and loss 
of soft tissue suggest malignancies. MRI provides superior 
soft tissue resolution; fat suppression around the facial 
sinuses, the pterygopalatine fossa and the infratemporal 
fossa increase the sensitivity of this method for tumor 
extension. MRI also differentiates the tumor, muscles, 
secretions, and mucous thickening better, and is superior 
when assessing perineural and perivascular structures, and 
intracranial invasion.2,12
The prognosis of patients with rhabdomyosarcomas 
depends on the primary site, tumor size, the histological 
subtype and tumor staging, the latter according to the 
Intergroup Rhabdomyosarcoma Study Group (IRSG) 
criteria, which is based on disease extent, and local and 
regional resectability (Table 1).5,9 Tumors of the orbit have 
a better prognosis; parameningeal (including nasal cavity 
tumors), nasopharyngeal, paranasal sinus, middle ear, 
mastoid, infratemporal fossa, and pterygopalatine fossa 
tumors have a worse prognosis because of the possibility 
of subarachnoid spread.2,3,4,8
Table 1. Groups for surgery and pathology5
GROUP DEFINITION
I
Localized tumor, fully resected with free surgical mar-
gins and no regional lymph node involvement
II
Localized tumor, resected macroscopically: (A) micros-
copic disease along the margins, (B) affected regional 
lymph nodes, (C) both A and B
III
Localized tumor, with residual disease after incomplete 
resection or biopsy only
IV Distance metastases present upon the diagnosis
Having established a diagnosis of rhabdomyosar-
coma, the next step is to evaluate the extent of disease 
before initiating therapy.
The clinical assessment includes a thoracic CT, a 
bone marrow biopsy, a bone scintigraphy, and a cranial 
base and brain MRI.5 The lungs are the most common site 
for distance metastases.
Treatment should be individualized for each 
patient.8 Survival in patients with head and neck rha-
bdomyosarcomas has increased with multidisciplinary 
therapy, which comprises chemotherapy, surgery, and 
radiotherapy.2,6,7
Patients with recurring rhabdomyosarcomas have a 
worse prognosis. The choice of therapy is based on several 
factors such as the site of recurrence or prior therapy.5
The purpose of this study was to review 24 cases 
of patients that were diagnosed and treated in a specific 
hospital and to compare the data with findings in the 
literature.
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SERIES AND METHOD
A retrospective review was undertaken of the recor-
ds of 24 patients with head and neck rhabdomyosarcomas 
that were diagnosed and treated at a specific hospital from 
1994 to 2008.
A descriptive analysis was made of age, sex, the 
clinical presentation of tumors, the histological subtype, the 
site of the primary tumor, and the type of therapy; these 
patients were monitored and the data was compared with 
findings in the literature, as reviewed in Medline.
RESULTS
There were 24 patients, 13 (54.17%) male and 11 
(45.83%) female. The mean age was 7.79 years (standard 
deviation - 9.51). The earliest diagnosis was made at bir-
th, and the most advanced age at diagnosis was 47 years 
(Chart 1).
The clinical picture and the physical examination 
at diagnosis and after varied depending on the tumor 
site. Patients with orbitary subsites course with rapidly 
progressive bulging and inflammation in the orbit. Peri-
pheral facial otalgia and paralysis were commonly found 
in patients with mastoid rhabdomyosarcomas. Symptoms 
and physical findings varied when the primary tumor was 
located in the face and rhinopharynx; these included bul-
ging, facial asymmetry or cellulitis, nasal block, rhinorrhea, 
snoring, epistaxis, odynophagia, facial paralysis, and loss 
of weight. A few patients were initially mistakenly treated 
for sinusitis, otitis or tonsillitis.
All patients underwent CT and MRI of the face and 
cranium to assess the tumor site, extent, and intracranial 
invasion. Intracranial invasion was found in 10 patients 
(41.67%); metastases at the time of diagnosis or during the 
progression of disease were present in 12 patients (50%). 
The main metastatic sites were the bones, lungs, menin-
ges, the central nervous system, and neck lymph nodes.
Chemotherapy was done in all patients. Supplemen-
tary radiotherapy was done in 15 patients (62.5%); only 4 
patients (16.67%) underwent surgery, which consisted of 
partial resection in two cases and orbit exenteration in two 
cases. Death ensued in 8 patients; 6 patients were tumor-
free at the time of discharge, and were followed up in the 
outpatient unit. Recurrence occurred in two patients one 
year after the end of therapy. Other patients were lost to 
follow-up and could not be found to provide information.
DISCUSSION
The rhabdomyosarcoma is the most common soft 
tissue sarcoma in childhood; it is located mainly in the 
head and neck, followed by the genitourinary tract and 
the limbs.3,13,14
Chart 1. Distribution of patients according to age.
The distribution according to the histological types 
was as follows: 16 embryonic (66.67%), 3 alveolar (12.5%), 
and 1 botryoid (4.17%); the subtype was not classified in 
4 patients (16.67%) (Chart 2).
Chart 2. Distribution according to the histological subtype.
The interval between the onset of symptoms and 
the final diagnosis was about two months in most patients.
Tumor subsites were parameningeal in 19 cases 
(79.1%), orbitary in three cases (12.5%), and parameningeal 
in two cases (8.3%). Among the parameningeal tumors the 
primary sites were: 9 cases in the face (47.3%), 5 cases in 
the temporal region (26.3%), 4 cases in the rhinopharynx 
(21.05%), 1 in the maxillary sinus (5.2%). Of the parame-
ningeal tumors, one was located in the parotid and one 
in the neck and base of tongue (Chart 3).
Chart 3. Distribution according to the subsite.
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There are other soft tissue sarcomas in adults, such 
as liposarcomas, histiocytomas, angiosarcomas, and leio-
miosarcomas.13
These tumors have a bimodal peak incidence, the 
first peak occurring in children aged from 2 to 6 years and 
the second peak occurring in adolescence. There is a slight 
male predisposition for sarcomas tumor.13,14
The mean age in out sample was 7.79 years; ma-
les predominated slightly (54.17%) compared to females 
(45.83%). Lyos et al. found similar results in a study of 134 
patients where the mean age was 7 years and the male to 
female ratio was 1.2:1.14
Quaglia et al. also found a bimodal age distribution 
with a peak in the first two years of life and another in 
late adolescence. In their study, the age at diagnosis had 
an independent effect on the survival of patients with 
invasive, but not metastatic, tumors. The few reports of 
rhabdomyosarcomas in adult have sown that survival is 
worse compared to children, notwithstanding multimodal 
therapy.15
The embryonic subtype was the most common in 
our review, followed by the alveolar subtype; according 
to the literature, these are also the most common forms 
in children. In three children with parameningeal alveolar 
rhabdomyosarcomas, two had distance metastases (one in 
the meninges and one in bones and lungs) and died. The 
third patient have local invasion to the temporal bone, and 
responded to therapy; this patient was disease-free in the 
follow-up period. Although botryoid tumors have a better 
prognosis according to published results, our patient with 
this subtype had local invasion to the posterior fossa and 
metastases to bones, meninges and the central nervous 
system. We found no follow-up data on this patient. No 
pleomorphic subtype was found, which concurs with 
published results that suggest this tumor occurs almost 
exclusively in adults.10
Parameningeal sites comprise half of all cases of 
head and neck rhabdomyosarcomas and 17% of rhab-
domyosarcoma cases in general. The IRS-I considers the 
head and neck as unfavorable sites because critical anato-
mical structures may be invaded, complete resection may 
not be possible, and early leptomeningeal invasion may 
occur. Furthermore, these sites are less visible compared 
to superficial head and neck sites, which implies in de-
layed diagnoses.7,16 The orbit as a site comprises about 25 
to 30% of head and neck rhabdomyosarcomas, and 10 to 
20% of all rhabdomyosarcomas;11 the prognosis is better 
compared to tumors in parameningeal sites.12,17 The three 
patients with orbit rhabdomyosarcomas had no intracranial 
invasion or metastases at the time of diagnosis. The two pa-
tients with non-parameningeal tumors had no intracranial 
invasion, but had distance metastases. Of 19 patients with 
parameningeal tumors, three had no intracranial invasion 
or metastases, which concurs with the literature that this 
site has a worse prognosis.
Neves et al. found that 100% of patients with 
rhabdomyosarcomas in parameningeal sites died mostly 
because of tumor progression, confirming that tumors in 
this site have a worse prognosis. In this study, the orbit 
was the most frequent site in head and neck; it had the 
lowest death rate, which was mostly due to complications 
of therapy.13
The clinical response to treatment depends on 
the site of the primary tumor, the histological subtype, 
the tumor size, the patient’s age, and the extent of the 
disease.3,5,18,19,20
International study protocols such as those develo-
ped by the United States rhabdomyosarcoma intergroup5 
in 1972, and the malignant mesenchymal tumor study 
(MMT) which the International Society of Pediatric On-
cology (SIOP) undertook in Europe, have increased our 
knowledge about this disease and improved the survival 
of patients with rhabdomyosarcomas.5,17 The long-term 
survival rate for these patients with non-metastatic disease 
is above 70%.20,21 However, tumors are generally diagnosed 
when they are at an advanced stage with local invasion.8
Authors in the literature have advocated multimodal 
therapy for rhabdomyosarcomas; this involves individuali-
zed systemic chemotherapy, surgery, and radiotherapy, ac-
cording to the initial presentation of the tumor.2,5,21 The IRS 
recommends surgery at first if there will be no functional 
and/or esthetic loss, followed by chemotherapy. Patients 
where the tumors are fully resected have a better prog-
nosis. Some patients with initially non-resectable tumors 
may undergo surgery for removing residual tumor mass 
after chemotherapy. Radiotherapy is indicated for alveolar 
subtype rhabdomyosarcomas or in patients with residual 
tumors after the initial treatment.5,10,18 Hidden lymph node 
metastases are uncommon; therefore, preventing neck 
dissection is not indicated. Surgery is not always feasible, 
especially in difficult anatomical areas or for tumors that 
invade intracranial structures.17
MMT comprises chemotherapy followed by alterna-
tive chemotherapy if there is a poor response to the initial 
treatment; the aim is to avoid local therapy because of its 
complications (morbidity of surgery and the side effects 
of radiotherapy).5 The gold standard is an association of 
vincristine, cyclophosphamide and actinomycin-D.5,18
Jochen et al. carried out a retrospective study of 
15 nose and paranasal sinus rhabdomyosarcoma cases, 
and reported that there was a trend for superior clinical 
responses in patients with embryonic rhabdomyosarcomas 
and no intracranial invasion and those patients treated with 
surgery followed by radiochemotherapy. Complications 
were seen in 6 of 15 patients that underwent radiotherapy; 
these included epilepsy, cerebral radionecrosis, optic nerve 
radionecrosis, growth disorders, and polyneuropathy.8
Beverly et al. reviewed the data of 47 patients with 
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superficial rhabdomyosarcomas of the face and conclu-
ded that these patients often presented resectable located 
lesions upon the diagnosis. Favorable prognostic factors 
included age below 12 years, the female sex, the embryo-
nic subtype, and absence of lymph node metastases.18
Our review showed that all patients underwent 
chemotherapy, as defended in the literature. Alternative 
therapy was given to 19 patients; 15 of these patients un-
derwent radiotherapy and 4 underwent surgery. Survival 
data were not available.
CONCLUSION
Head and neck rhabdomyosarcomas often pre-
sent non-specific symptoms. Consequently, delays in the 
diagnosis and therapy occur in many cases, especially in 
parameningeal tumors. Early identification optimizes the 
potential for cure and decreases the morbidity of therapy, 
again especially in parameningeal tumors.
Individualized multimodal therapy is needed for 
these patients; it depends on the tumor size and site, the 
histological subtype, local invasion, and distance metas-
tases. Surgery should be done as the first treatment if it 
causes no functional or esthetic harm, followed by systemic 
chemotherapy. Radiotherapy is indicated for the alveolar 
subtype of rhabdomyosarcomas or for patients with resi-
dual tumors following the first treatment.
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